NCT03258567 2026-05-22Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting40 enrolled